Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy

Yusuke Fukao, Hitoshi Suzuki, Jin Sug Kim, Kyung Hwan Jeong, Yuko Makita, Toshiki Kano, Yoshihito Nihei, Maiko Nakayama, Mingfeng Lee, Rina Kato, Jer Ming Chang, Sang Ho Lee, Yusuke Suzuki

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


In patients with IgA nephropathy (IgAN), circulatory IgA1 and IgA1 in the mesangial deposits contain galactose-deficient IgA1 (Gd-IgA1). Some of the Gd-IgA1 from the glomerular deposits is excreted in the urine and thus urinary Gd-IgA1 may represent a disease-specific marker. We recruited 338 Japanese biopsy-proven IgAN patients and 120 patients with other renal diseases (disease controls). Urine samples collected at the time of renal biopsy were used to measure Gd-IgA1 levels using a specific monoclonal antibody (KM55 mAb). Urinary Gd-IgA1 levels were significantly higher in patients with IgAN than in disease controls. Moreover, urinary Gd-IgA1 was significantly correlated with the severity of the histopathological parameters in IgAN patients. Next, we validated the use of urinary Gd-IgA1 levels in the other Asian cohorts. In the Korean cohort, urinary Gd-IgA1 levels were also higher in patients with IgAN than in disease controls. Even in Japanese patients with IgAN and trace proteinuria (less than 0.3 g/gCr), urinary Gd-IgA1 was detected. Thus, urinary Gd-IgA1 may be an early disease-specific biomarker useful for determining the disease activity of IgAN.

Original languageEnglish
Article number3173
JournalJournal of Clinical Medicine
Issue number11
Publication statusPublished - 1 Jun 2022


  • IgA nephropathy
  • KM55
  • urinary galactose-deficient IgA1


Dive into the research topics of 'Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy'. Together they form a unique fingerprint.

Cite this